Medicare Enrolled
Dr. Ray Page, D.O.
Hematology & Oncology · Weatherford, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Page from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Page? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Page
Dr. Ray Page is a hematology & oncology in Weatherford, TX, with 19 years in practice. Based on federal Medicare data, Dr. Page performed 107,197 Medicare services across 1,559 unique beneficiaries.
Between the years covered by Open Payments, Dr. Page received a total of $48,461 from 91 pharmaceutical and/or device companies across 646 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Page is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 6% volume in TX$ $48,461 industry payments
Medicare Practice Summary
Medicare Utilization ↗107,197
Medicare services
Top 6% in TX for hematology & oncology
1,559
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,642 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 39,000 | $1 | $3 |
| Filgrastim injection (Nivestym) for white blood cells | 36,480 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 19,800 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,000 | $19 | $40 |
| Dexamethasone injection (steroid) | 2,010 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,770 | $1 | $52 |
| Office visit, established patient (30-39 min) | 785 | $91 | $275 |
| Office visit, established patient, complex (40-54 min) | 405 | $131 | $350 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 392 | $22 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 379 | $97 | $412 |
| Injection of additional new drug or substance into vein | 332 | $12 | $70 |
| COVID-19 test, self-administered | 314 | $12 | $30 |
| Drug injection, under skin or into muscle | 301 | $11 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 265 | $49 | $202 |
| Injection, zoledronic acid, 1 mg | 215 | $6 | $300 |
| Injection, triptorelin pamoate, 3.75 mg | 189 | $299 | $1,000 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 178 | $46 | $190 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 170 | $46 | $160 |
| Administration of chemotherapy into vein, each additional hour | 159 | $21 | $93 |
| Ct scan of chest with contrast | 124 | $53 | $401 |
| Injection, diphenhydramine hcl, up to 50 mg | 119 | $1 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 106 | $15 | $60 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 96 | $1 | $5 |
| CT scan of abdomen and pelvis with contrast | 91 | $159 | $681 |
| Irrigation of implanted venous access drug delivery device | 85 | $18 | $69 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 75 | $24 | $105 |
| Office visit, established patient (20-29 min) | 52 | $62 | $175 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 51 | $36 | $120 |
| New patient office visit, complex (60-74 min) | 47 | $161 | $500 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 36 | $1,125 | $4,069 |
| Advance care planning consultation, first 30 min | 30 | $61 | $250 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 28 | $106 | $450 |
| Chronic care management, first 20 min/month | 27 | $46 | $161 |
| CT scan of chest, without contrast | 21 | $37 | $300 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $22 | $155 |
| New patient office visit (45-59 min) | 17 | $122 | $400 |
| Injection of drug or substance into vein | 16 | $28 | $145 |
| Ct scan of abdomen and pelvis without contrast | 14 | $66 | $338 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
37.0% high complexity
60.8% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$48,461
Total received (2018-2024)
Avg $6,923/year across 7 years
Top 13% in TX for hematology & oncology
91
Companies
646
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$24,778 (51.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,334 (29.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$9,349 (19.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,928
2023$17,112
2022$1,683
2021$7,473
2020$4,303
2019$8,170
2018$6,791
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$5,289
Verastem, Inc.
$5,185
Astellas Pharma US Inc
$4,210
ABBVIE INC.
$3,425
Janssen Biotech, Inc.
$2,979
Puma Biotechnology, Inc.
$2,560
Takeda Pharmaceuticals U.S.A., Inc.
$2,434
AstraZeneca Pharmaceuticals LP
$1,966
G1 Therapeutics, Inc.
$1,515
Jazz Pharmaceuticals Inc.
$1,312
Regeneron Pharmaceuticals, Inc.
$1,208
TESARO, Inc.
$1,132
JAZZ PHARMACEUTICALS INC.
$1,123
Amgen Inc.
$1,112
Novartis Pharmaceuticals Corporation
$909
E.R. Squibb & Sons, L.L.C.
$903
Seattle Genetics, Inc.
$887
Genentech USA, Inc.
$812
PFIZER INC.
$648
PUMA BIOTECHNOLOGY, INC.
$632
Ipsen Biopharmaceuticals, Inc
$578
Lilly USA, LLC
$522
Gilead Sciences, Inc.
$438
GENZYME CORPORATION
$366
Merck Sharp & Dohme Corporation
$325
AbbVie, Inc.
$315
Exelixis Inc.
$285
Merck Sharp & Dohme LLC
$285
Celgene Corporation
$280
Incyte Corporation
$265
GlaxoSmithKline, LLC.
$214
Regeneron Healthcare Solutions, Inc.
$204
Bayer Healthcare Pharmaceuticals Inc.
$195
Clovis Oncology, Inc.
$185
Genmab U.S., Inc.
$176
Bayer HealthCare Pharmaceuticals Inc.
$165
Seagen Inc.
$165
Spectrum Pharmaceuticals Inc.
$152
Tempus AI, Inc
$149
Stemline Therapeutics Inc.
$141
Teva Pharmaceuticals USA, Inc.
$140
Blueprint Medicines Corporation
$139
Boehringer Ingelheim Pharmaceuticals, Inc.
$127
Eisai Inc.
$127
Pharmacyclics LLC, An AbbVie Company
$122
Kite Pharma, Inc.
$116
Pharmacosmos Therapeutics Inc.
$116
F. Hoffmann-La Roche AG
$110
EMD Serono, Inc.
$106
PharmaEssentia USA Corporation
$101
ASD SPECIALTY HEALTHCARE, LLC
$97
Helsinn Therapeutics (U.S.), Inc.
$94
SOBI, INC
$89
Taiho Oncology, Inc.
$83
Karyopharm Therapeutics Inc.
$79
Immunocore Limited
$72
Rigel Pharmaceuticals, Inc.
$67
EISAI INC.
$61
Sirtex Medical Inc
$58
TAIHO ONCOLOGY, INC.
$53
TG THERAPEUTICS, INC.
$50
SERVIER PHARMACEUTICALS LLC
$48
Apellis Pharmaceuticals, Inc.
$46
Mirati Therapeutics, Inc.
$45
ARRAY BIOPHARMA INC
$43
Sun Pharmaceutical Industries Inc.
$42
TerSera Therapeutics LLC
$42
MorphoSys, US Inc.
$41
Foundation Medicine, Inc.
$38
Janssen Scientific Affairs, LLC
$36
BeiGene USA, Inc.
$34
ADC Therapeutics America, Inc.
$33
Epizyme, Inc.,
$32
Organon LLC
$30
Adaptive Biotechnologies Corporation
$30
Kyowa Kirin, Inc.
$28
Janssen Pharmaceuticals, Inc
$26
Coherus Biosciences Inc.
$24
Acrotech Biopharma Inc.
$21
Novocure Inc.
$20
SpringWorks Therapeutics, Inc.
$16
Array BioPharma Inc.
$16
Deciphera Pharmaceuticals Inc.
$15
CTI BioPharma Corp.
$15
BTG International, Inc.
$14
Acrotech Biopharma LLC
$14
Dova Pharmaceuticals
$13
Heron Therapeutics, Inc.
$12
Aurobindo Pharma USA, Inc.
$12
TOLMAR Pharmaceuticals, Inc.
$11
INSYS Therapeutics Inc
$11
Top 3 companies account for 30.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALPROLIX · ALUNBRIG · AUGTYRO · AYVAKIT · Alecensa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DAURISMO · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · GRANIX · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Non-Covered Product · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Odomzo · Oncology · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TALZENNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Tivdak · Trodelvy · UKONIQ · Udenyca · VELCADE · VENCLEXTA · VERZENIO · VONJO · VORAXAZE · VOTRIENT · Venclexta · Vonjo · Vyloy · XALKORI · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (51%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $45 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
5
Per 100K population
3.2
County median income
$102,099
Nearest hospital
MEDICAL CITY WEATHERFORD
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Page is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and high industry engagement (consulting-driven, top 13%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Page experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Page performed 39,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Page receive payments from pharmaceutical companies?
Yes. Dr. Page received a total of $48,461 from 91 companies across 646 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Page's costs compare to other hematology & oncologys in Weatherford?
Dr. Page's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Page) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Weatherford
Browse hematology & oncologys in Weatherford ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc..
By company
Verastem, Inc. Payments to Doctors
See all physicians who received payments from Verastem, Inc..
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology